These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 21455857)

  • 1. Thrombosis and sickle cell disease.
    De Franceschi L; Cappellini MD; Olivieri O
    Semin Thromb Hemost; 2011 Apr; 37(3):226-36. PubMed ID: 21455857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
    Wood KC; Granger DN
    Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.
    Ataga KI; Cappellini MD; Rachmilewitz EA
    Br J Haematol; 2007 Oct; 139(1):3-13. PubMed ID: 17854302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology.
    Stuart MJ; Setty BN
    Pediatr Pathol Mol Med; 2001; 20(1):27-46. PubMed ID: 12673843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redox-dependent impairment of vascular function in sickle cell disease.
    Aslan M; Freeman BA
    Free Radic Biol Med; 2007 Dec; 43(11):1469-83. PubMed ID: 17964418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology and treatment of sickle cell disease.
    Raphael RI
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):492-505. PubMed ID: 16167028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sickle cell disease: loss of the blood's WD40?
    Lancaster JR
    Trends Pharmacol Sci; 2003 Aug; 24(8):389-91. PubMed ID: 12915046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion.
    Francis RB
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):341-53. PubMed ID: 1893065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical trials of new therapeutic pharmacology for sickle cell disease].
    Brugnara C; de Franceschi L
    Sante; 2006; 16(4):263-8. PubMed ID: 17446160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypercoagulability in sickle cell disease: a curious paradox.
    Ataga KI; Orringer EP
    Am J Med; 2003 Dec; 115(9):721-8. PubMed ID: 14693325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease.
    Garrido VT; Proença-Ferreira R; Dominical VM; Traina F; Bezerra MA; de Mello MR; Colella MP; Araújo AS; Saad ST; Costa FF; Conran N
    Br J Haematol; 2012 Sep; 158(6):788-97. PubMed ID: 22775554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy.
    Hebbel RP; Osarogiagbon R; Kaul D
    Microcirculation; 2004 Mar; 11(2):129-51. PubMed ID: 15280088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving treatment paradigms in sickle cell disease.
    Jagadeeswaran R; Rivers A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):440-446. PubMed ID: 29222291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiological insights in sickle cell disease.
    Odièvre MH; Verger E; Silva-Pinto AC; Elion J
    Indian J Med Res; 2011 Oct; 134(4):532-7. PubMed ID: 22089617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood rheology abnormalities and vascular cell adhesion mechanisms in sickle cell trait carriers during exercise.
    Connes P; Hue O; Tripette J; Hardy-Dessources MD
    Clin Hemorheol Microcirc; 2008; 39(1-4):179-84. PubMed ID: 18503123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiologically based drug treatment of sickle cell disease.
    Steinberg MH
    Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.
    Ataga KI; Moore CG; Hillery CA; Jones S; Whinna HC; Strayhorn D; Sohier C; Hinderliter A; Parise LV; Orringer EP
    Haematologica; 2008 Jan; 93(1):20-6. PubMed ID: 18166781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythrocyte adhesion in sickle cell disease.
    Parise LV; Telen MJ
    Curr Hematol Rep; 2003 Mar; 2(2):102-8. PubMed ID: 12901140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.